e Pseudomonas aeruginosa can develop resistance to polymyxin as a consequence of mutations in the PhoPQ regulatory system, mediated by covalent lipid A modification. Transposon mutagenesis of a polymyxin-resistant phoQ mutant defined 41 novel loci required for resistance, including two regulatory systems, ColRS and CprRS. Deletion of the colRS genes, individually or in tandem, abrogated the polymyxin resistance of a ⌬phoQ mutant, as did individual or tandem deletion of cprRS. Individual deletion of colR or colS in a ⌬phoQ mutant also suppressed 4-amino-L-arabinose addition to lipid A, consistent with the known role of this modification in polymyxin resistance. Surprisingly, tandem deletion of colRS or cprRS in the ⌬phoQ mutant or individual deletion of cprR or cprS failed to suppress 4-amino-L-arabinose addition to lipid A, indicating that this modification alone is not sufficient for PhoPQ-mediated polymyxin resistance in P. aeruginosa. Episomal expression of colRS or cprRS in tandem or of cprR individually complemented the Pm resistance phenotype in the ⌬phoQ mutant, while episomal expression of colR, colS, or cprS individually did not. Highly polymyxin-resistant phoQ mutants of P. aeruginosa isolated from polymyxin-treated cystic fibrosis patients harbored mutant alleles of colRS and cprS; when expressed in a ⌬phoQ background, these mutant alleles enhanced polymyxin resistance. These results define ColRS and CprRS as two-component systems regulating polymyxin resistance in P. aeruginosa, indicate that addition of 4-amino-L-arabinose to lipid A is not the only PhoPQ-regulated biochemical mechanism required for resistance, and demonstrate that colRS and cprS mutations can contribute to high-level clinical resistance.
T he polymyxins (Pm), a family of cyclic oligopeptides with activity against Pseudomonas aeruginosa and other Gram-negative pathogens, are increasingly important in the treatment of invasive infections in critically ill patients and airway infections in those with cystic fibrosis (CF) (1, 2) . First-line treatment of these infections often involves intravenous or inhaled combinations of antipseudomonal beta-lactams, aminoglycosides, fluoroquinolones, and other agents. Repeated use of these first-line agents imposes selection pressure leading to multidrug-resistant strains of P. aeruginosa (3) (4) (5) . When this occurs, the clinically available forms of Pm, namely, Pm B sulfate (PMB) and colistimethate, the prodrug form of colistin (CST) (also known as Pm E), become key components of second-line regimens.
Pm binds to lipopolysaccharide (LPS), the major constituent of the Gram-negative outer membrane, promoting membrane permeabilization and diffusion of peptide through the periplasm to the inner membrane, where Pm insertion disrupts cellular respiration and results in cell lysis (6) . Unfortunately, the prevalence of Pm-resistant (Pm r ) clinical strains of P. aeruginosa and other Gram-negative pathogens is increasing (7) (8) (9) (10) (11) (12) (13) ; such strains are generally resistant to both PMB and CST.
At a biochemical level, Pm resistance of P. aeruginosa and other Gram-negative pathogens is strongly associated with covalent modification of LPS, most specifically with the addition of 4-amino-L-arabinose (L-Ara4N) to the phosphate groups of its lipid A and core oligosaccharide components (14) (15) (16) . Genes in the arnBCADTEF-pmrE operon encode enzymes responsible for synthesis and transfer of L-Ara4N to LPS (17, 18) . This aminosugar modification is thought to hinder charge interactions between phosphate groups within LPS and amino groups within the cyclic Pm oligopeptide.
In contrast to their hierarchical regulation of Pm resistance in Salmonella enterica, the PhoPQ and PmrAB two-component systems of P. aeruginosa regulate Pm resistance convergently, at least in part by activating transcription of the arnBCADTEF-pmrE operon in response to antimicrobial peptide exposure or divalent cation depletion (17) (18) (19) (20) or as a consequence of mutation (13, 16, (21) (22) (23) (24) (25) . Recently, the ParRS two-component system has also been found to play a role in Pm resistance in P. aeruginosa (26, 27) . We hypothesized that additional regulatory systems interact with these known two-component systems to modulate Pm resistance and that mutations in such systems might contribute to high-level clinical resistance. The primary objective of this study was to identify additional regulatory systems contributing to PhoPQ-mediated Pm resistance in highly resistant clinical strains; a secondary objective was to define loci encoding additional structural elements required for PhoPQ-mediated Pm resistance.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Laboratory strains and clinical isolates of P. aeruginosa used in this study are listed in Table 1 . Clinical isolates were from the sputum of patients followed in the CF clinic at Rigshospitalet, Copenhagen, Denmark; the Institutional Review Board of Massachusetts General Hospital reviewed and approved their use in this study. Escherichia coli DH5␣ was used as a host for manipulation of recombinant plasmids. P. aeruginosa and E. coli were grown at 30°C or 37°C on lysogeny agar (LA) plates or in lysogeny broth (LB) with aeration. Antibiotics were used at the following concentrations for selection and maintenance of plasmids: 50 mg/liter kanamycin or 10 mg/liter gentamicin (GEN) for E. coli DH5␣ and 50 to 100 mg/liter GEN for P. aeruginosa PAK and its derivatives. Strains were stored at Ϫ80°C in LB supplemented with 16% glycerol.
Molecular methods. Bacterial plasmids were isolated using the QIAprep spin kit (Qiagen, Valencia, CA), and bacterial chromosomal DNA was isolated using the MasterPure kit (Epicentre Biotechnologies, Madison, WI). Plasmids were introduced into P. aeruginosa by electroporation (28) . PCR amplification was performed as described previously (23) using oligonucleotide primers (see Table S1 in the supplemental material) that were designed according to data from the Pseudomonas. com database (29) . Sanger sequencing of bacterial plasmids and chromosomal DNA was performed using oligonucleotide primers listed in Table  S1 . Whole-genome sequencing of bacterial chromosomal DNA was performed as described previously (30) . For each genome, a random-fragment library was constructed using a custom protocol. Briefly, genomic DNA (gDNA) samples were sheared by sonication and end repaired using the End-It DNA end repair kit (Epicentre). Repaired fragments were subjected to A tailing using Taq DNA polymerase (Roche Inc. USA, Chicago, IL); custom "Y" adaptors were then ligated to A-tailed fragments using T4 DNA ligase (New England BioLabs, Beverly, MA). Libraries were size selected and quantified using standard agarose gel electrophoresis. Sequencing (single-end, 36-bp reads) was performed on an Illumina GA IIx genome analyzer according to the manufacturer's instructions (Illumina, San Diego, CA). Alignments of short reads were performed using the software program MAQ (31) . De novo assembly of unmappable and poorly mapped reads was performed using the program EDENA (32) .
Transposon mutagenesis. To create a set of random transposon mutants, the Pm r strain PAK ⌬pmrAB phoQ6 (23) was conjugated with the donor strain SM10 pir pUT::mTn5-aacC1 (kindly provided by E. P. Greenberg, University of Washington, Seattle, WA), using the filter method (33) . The conjugation mix was plated on LA supplemented with 100 mg/liter GEN and 10 mg/liter chloramphenicol to select for transconjugants and counterselect against the donor strain. Individual transconjugants were manually arrayed in 96-well plates containing LB with 20% glycerol (0.2 ml per well) and stored at Ϫ80°C.
To screen the set of PAK ⌬pmrAB phoQ6 mTn5-aacC1 transconjugants (n ϭ 8,836) for loss of Pm resistance, a 96-pin replicator was used to inoculate 96-well plates containing LB with 20 mg/liter GEN (0.2 ml per well), which were then incubated overnight at 30°C. The 96-pin replicator was used to transfer the regrown transconjugant set to OmniTray plates containing LA with 1 mM MgCl 2 and 0 or 100 mg/liter PMB, the highest concentration that consistently permitted growth of pin-inoculated PAK ⌬pmrAB phoQ6 in pilot experiments. The inoculated plates were incubated at 30°C overnight and then at ambient temperature for six additional days. Growth was examined and recorded on days 1, 2, 3, and 7. Transconjugants with loss of Pm resistance (n ϭ 127) were retested using the PMB plate assay (0, 5, and 20 mg/liter).
Transposon insertion sites were identified using a two-step semidegenerate PCR method (34) . A mixture of semidegenerate primers (SM1368 and SM1369) was used in combination with the mini-Tn5 (mTn5)-specific primer (SM1373) in the first PCR step. A primer designed to hybridize with the 5= (nondegenerate) portion of the semidegenerate primers (SM1370) was used in combination with a nested mTn5-specific primer (SM1371) in the second PCR step. The product of the second PCR step was sequenced using primer SM1371. The insertion site for some transconjugants was reconfirmed using locus-specific primers. Primer sequences are listed in Table S1 in the supplemental material.
Strain construction. Chromosomal deletions were constructed as described previously (23) using the Gateway cloning system (Invitrogen, Carlsbad, CA), with specific oligonucleotide primers listed in Table S1 in the supplemental material. Each deletion was marked with a unique HindIII restriction site; to confirm deletions, the region surrounding the target gene was PCR amplified from chromosomal DNA and digested with the restriction endonuclease HindIII to detect the unique marker. For strains in which the phoQ gene was deleted, this was performed as the final step of strain construction to minimize the occurrence of secondary suppressor mutations (23) . Expression plasmids were constructed using Gateway technology as described previously (23), with specific oligonucleotide primers listed in Table S1 . The Quick-Change site-directed mutagenesis method (Stratagene) was used to introduce the CprS R241C mutation into expression plasmids containing a wild-type (WT) cprS allele, according to the manufacturer's instructions. The PCR amplification step was performed using the oligonucleotide primers SM1620 and SM1621, with plasmid pDONR221::colR ϩ S ϩ as the template. To eliminate the parental DNA template, this PCR mixture was incubated with DpnI (New England BioLabs) at 37°C for 1.5 h. To confirm the mutagenesis product, the oligonucleotide primers SM1562, SM1563, SM1516, SM1517, and SM1624 were used.
Susceptibility testing. CST agar dilution testing and PMB plate assay were carried out and interpreted as described previously (23, 35) with the following modifications. LA plates and LB were supplemented with 1 mM MgCl 2 . For testing of strains that contained expression plasmids, inocula were prepared using prolonged induction (24-h exposure to inducer) or brief induction (4-h exposure to inducer). For prolonged induction, strains with pJN105D-derived plasmids were streaked to LA containing GEN and L-arabinose (L-Ara) at 0.1% (strong induction) or 0.025% (weak induction) and incubated at 30°C for 20 h. Several colonies from this plate were inoculated into LB containing GEN and 0.1% or 0.025% L-Ara and incubated at 30°C with aeration for 4 h. For brief induction, strains with pJN105D-derived plasmids were streaked to LA containing GEN and incubated at 30°C for 20 h. Several colonies from this plate were inoculated into LB containing GEN and incubated at 30°C with aeration for 20 h. An aliquot from this culture was diluted 1:50 into LB containing GEN and 0.1% or 0.025% L-Ara and incubated at 30°C with aeration for 4 h. To test the plasmid-containing strains, 0.1% or 0.025% L-Ara was added to LA for the PMB plate assay. For the PMB plate assay, the MIC was defined as the lowest concentration with Ͻ10% survival. For CST agar dilution and PMB plate assays, an MIC of Ն8 but Ͻ64 mg/liter was interpreted as low-level resistance, Ն64 but Ͻ512 mg/liter was interpreted as moderate resistance, and Ն512 mg/liter was interpreted as high-level resistance.
Lipid A isolation and analysis. LPS was isolated after growth in LB with 1 mM MgCl 2 (36) . Lipid A was isolated from LPS by hydrolysis (37) . The lipid A structure was analyzed using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry in negativeion, linear mode (38) . All MALDI-TOF analyses were performed on a Waters MALDI micro MX mass spectrometer. The matrix used for lipid A analysis was 5-chloro-2-mercaptobenzothiazole (20 mg/liter in 1:1 chloroform-methanol).
RESULTS

Transposon insertion in PA4381 (colR), PA3078 (cprS), or 39
other loci abrogates PhoPQ-mediated Pm resistance. To define loci necessary for PhoPQ-mediated Pm resistance, we analyzed a bank of transposon mutants of the Pm r P. aeruginosa strain PAK ⌬pmrAB phoQ6 (CST MIC, 8 mg/liter) (23) that had been created with a mini-Tn5 transposon carrying a selectable GEN resistance marker (mTn5-aacC1). A primary screen of transconjugants (n ϭ 8,836) on medium with or without PMB yielded 127 candidates. PMB plate assays repeated on at least two occasions confirmed 71 transconjugants with partial or complete loss of Pm resistance. PCR amplification and sequence analysis of 63 transconjugants revealed transposon insertion in 41 distinct loci (Table 2) ; for the other eight transconjugants, the transposon insertion site was not identified.
Given the phoQ strain background and the known role of the L-Ara4N biosynthetic operon in Pm resistance, identification of transposon insertions within phoP (PA1179), arnC (PA3553), and arnT (PA3556) provided an important validation of the method. The transposon analysis implicated cell wall biogenesis genes, such as oprF (PA1777), galU (PA2023), oprI (PA2853), prc (PA3257), and mpl (PA4020); the pagL gene (PA4661) encoding a lipid A deacylase (39, 40) ; genes within the LPS core biosynthesis cluster (PA5002-5004), including wapH and mig-14 (41, 42) ; and algC (PA5322), a gene required for biosynthesis of full-length LPS (41) . The analysis also implicated a locus (PA4476) encoding a large hypothetical protein with C-terminal homology to the AsmA proteins of E. coli and Yersinia pestis; null mutations in asmA are associated with decreased LPS levels in E. coli (43) , while induction of asmA transcription is associated with increased antimicrobial peptide resistance in Y. pestis (44) . In addition to these loci, which are important for outer membrane stability, the analysis implicated an operon (PA1768-1766) encoding a probable zinc protease, a membrane-tethered transglutaminase, and an ␣-L-glutamate ligase homologue; each of these could plausibly contribute to antimicrobial peptide resistance through modification of proteins and peptides at the cell wall.
Some P. aeruginosa clinical isolates with stable Pm resistance do not have mutations in phoPQ, pmrAB, or parRS (data not shown), which encode three regulatory systems known to be involved in such resistance. This suggests that additional regulatory systems are involved in Pm resistance and might be mutated in such isolates. Transposon-disrupted loci encoding novel regulatory systems were therefore deemed to be of special interest for further analysis. Two such loci, PA4381 (disrupted in transconjugant strain 3882) and PA3078 (disrupted in transconjugant strain 3897), encode homologues of the ColRS two-component regulatory system of Pseudomonas fluorescens (45) and Pseudomonas putida (46) . PA4380, downstream of PA4381 on the minus strand of the PAO1 chromosome, encodes a sensor kinase previously designated colS (47); PA4381 encodes a response regulator that we designated colR. P. aeruginosa ColS shares 76% similarity with that of P. fluorescens, while the ColR homologues are 91% similar (29) . PA3078 encodes a sensor kinase, and the upstream locus PA3077 encodes the cognate response regulator; these were recently designated cprS and cprR, respectively (48) . P. aeruginosa CprS is 45% similar to ColS of P. fluorescens, while CprR is 68% similar to ColR of P. fluorescens. In addition, the transposon analysis identified PA1559, encoding a hypothetical protein; the CprRS system was previously shown to regulate this locus (48) .
Deletion of colRS or cprRS abrogates the Pm resistance of a P. aeruginosa ⌬phoQ strain. Similar to the phenotypic effect of the phoQ6 allele, which contains a frameshift mutation, phoQ deletion or disruption also confers Pm resistance in a phoP-dependent fashion (20, 22, 23) ; the CST MIC is 32 mg/liter for the PAK ⌬phoQ mutant, compared to 0.5 mg/liter for the PAK wild-type (WT) strain. To confirm the dependence of PhoPQ-mediated Pm resistance on the ColRS and CprRS two-component systems, strains with clean deletion of genes in the colRS and cprRS loci were constructed in the PAK WT and ⌬phoQ backgrounds. Deletion of colRS largely abrogated the Pm resistance that phoQ deletion confers in strain PAK (Fig. 1A) . Deletion of colR or colS in the ⌬phoQ background was similar in phenotypic effect to deletion of colRS (Fig. 1A) . The colRS deletions (⌬colR, ⌬colS, and ⌬colRS; strains 3749, 3751, and 3752, respectively) did not have a detectible effect on Pm susceptibility in the WT background (see Table  S2 in the supplemental material, which lists PMB plate assay MICs for strains without expression plasmids).
Deletion of cprRS in the ⌬phoQ background resulted in substantial loss of Pm resistance (Fig. 1B) . Deletion of cprR or cprS alone in the ⌬phoQ background was similar in phenotypic effect to ⌬cprRS. None of these cprRS deletions had a detectible effect on Pm susceptibility in the WT background (strains 3806, 3802, and 3804, respectively) when the mutants were grown under Mg 2ϩ -replete conditions (see Table S2 in the supplemental material).
Effect of colRS or cprRS deletion on lipid A 4-amino-L-arabinose modification in the PAK ⌬phoQ strain. Addition of L-Ara4N to the 1 and 4= phosphate groups of lipid A is associated with Pm resistance in P. aeruginosa and other Gram-negative organisms (49) . The arnBCADTEF-pmrE operon encodes enzymes responsible for biosynthesis and attachment of L-Ara4N to lipid A (50) . To examine the hypothesis that deletions in the colRS and cprRS loci abrogate Pm resistance through their effect on this modification, lipid A from the WT strain, ⌬phoQ mutant, and colRS or cprRS deletion mutants in the ⌬phoQ background was purified and analyzed by MALDI-TOF mass spectrometry.
Lipid A from the WT had major peaks at mass/charge ratio (m/z) 1,617 and 1,447 (Table 3) , corresponding to hexa-and penta-acylated species that differ in the presence or absence of 3-hydroxydecanoate (⌬m/z ϭ Ϫ170) ( Fig. 2A) . It also had a minor peak at m/z 1,685, corresponding to addition of palmitate (C16:0) to the penta-acylated species. Lipid A from the ⌬phoQ mutant had the major peaks at m/z 1,617 and 1,447, with addi- tional major peaks at m/z 1,578, 1,748, and 1,879 (Fig. 2B) , corresponding to addition of one or two L-Ara4N residues (⌬m/z ϭ ϩ131) to the hexa-and penta-acylated species ( Fig. 2A) . It also had minor peaks at m/z 1,709, corresponding to addition of two L-Ara4N residues to the penta-acylated species, and at m/z 1,685, 1,947, and 1,986, corresponding to addition of C16:0 to various species. Lipid A from the ⌬phoQ ⌬colR strain had major peaks at m/z 1,617 and 1,447 but none of the additional major peaks present in lipid A from the ⌬phoQ strain (Fig. 2C) and thus was largely indistinguishable from WT lipid A. Lipid A from the ⌬phoQ ⌬colS strain had major peaks at m/z 1,617 and 1,447 but only minor peaks at m/z 1,578 and 1,748 (Table 3) , indicating decreased L-Ara4N abundance compared to that for lipid A from the ⌬phoQ strain. Lipid A from these mutants had one or more minor peaks indicating the presence of C16:0.
Surprisingly, lipid A from the ⌬phoQ ⌬colRS strain had major peaks at m/z 1,617, 1,447, 1,578, and 1,748 (Fig. 2D) , indicating L-Ara4N abundance comparable to that of lipid A from ⌬phoQ, despite the diminished Pm resistance of this colRS mutant. It also had minor peaks indicating the presence of C16:0. Similarly, lipid A from the ⌬phoQ ⌬cprR, ⌬phoQ ⌬cprS, and ⌬phoQ ⌬cprRS strains had the same major peaks as lipid A from the ⌬phoQ strain, indicating abundant L-Ara4N modification, despite the diminished Pm resistance of these mutants (Table 3) .
Prolonged strong induction of episomal colRS WT allele in PAK ⌬phoQ ⌬colRS restores Pm resistance. Episomal expression of the colRS WT allele (derived from strain PAK) in the ⌬phoQ ⌬colRS strain restored Pm resistance (Fig. 3A) , in response to prolonged strong induction (0.1% L-Ara for 24 h), compared to that of the ⌬phoQ strain as a positive control. In contrast, brief strong induction (0.1% L-Ara for 4 h) of this allele was insufficient to complement the Pm susceptibility phenotype of the ⌬phoQ ⌬colRS strain (data not shown). Prolonged strong induction of colR ϩ in the ⌬phoQ ⌬colR strain or of colS ϩ in the ⌬phoQ ⌬colS strain also failed to complement the Pm susceptibility phenotype of these strains (see Table S3 in the supplemental material, which lists PMB plate assay MICs for strains with expression plasmids).
Prolonged weak induction of episomal colR21S21 mutant allele in PAK ⌬phoQ ⌬colRS restores Pm resistance. Previous work had shown that a P. aeruginosa clinical isolate (strain 1577) with high-level Pm resistance (CST MIC Ͼ 512 mg/liter) carries the phoQ21 mutant allele (23) . This strain was isolated from a Copenhagen CF patient continuously treated with inhaled CST.
Whole-genome sequencing of this strain revealed a point mutation in colR, C4912731T, resulting in a missense mutation (Asp32Asn) in the ColR receiver domain near the Asp51 active site. This mutation was not found in the whole-genome sequences of earlier phoQ21 mutants from the same patient, To define their role in clinical Pm resistance, these colRS mutant alleles, designated colR21S21, were PCR amplified and inserted into pJN105D. Prolonged strong induction of the bicistronic colR21S21 mutant allele in the ⌬phoQ ⌬colRS strain restored a level of Pm resistance similar to that conferred by the WT allele (Fig. 3B ). As seen with the WT allele, brief strong induction was insufficient to complement the Pm susceptibility phenotype, and prolonged strong induction of monocistronic colR21 in the ⌬phoQ ⌬colR strain (strain 4039) or of monocistronic colS21 in the ⌬phoQ ⌬colS strain (strain 4035) failed to complement Pm susceptibility (see Table S3 in the supplemental material). Interestingly, prolonged weak induction (0.025% L-Ara for 24 h) of colR21S21 in the ⌬phoQ ⌬colRS strain was sufficient to restore Pm resistance, whereas prolonged weak induction of the colRS WT allele was not (Fig. 3C) .
To determine the effect of the colRS WT and colR21S21 mutant alleles on Pm susceptibility independent of phoQ deletion, each was expressed in the ⌬colRS background (strains 4115 and 4113, respectively) with prolonged strong induction. These alleles did not decrease the Pm susceptibility of this strain, compared to results for an empty vector (see Table S3 ).
More surprisingly, prolonged strong induction of these alleles in the ⌬phoQ background (strains 4175 and 4173) failed to augment Pm resistance (see Table S3 ). This indicates that the effect of colR21S21 on Pm susceptibility is genetically recessive to the chromosomal colRS WT allele present in this strain background. Duration of cprR WT allele induction in ⌬phoQ ⌬cprRS strains determines Pm resistance level. The cprRS, cprR, and cprS WT alleles from PAK were inserted into pJN105D. In response to brief strong induction (0.1% L-Ara for 4 h), expression of the bicistronic cprRS WT allele in the ⌬phoQ ⌬cprRS strain restored moderate Pm resistance to a subpopulation of ϳ10 to 20% (Fig. 4A ), compared to results for the ⌬phoQ strain as a positive control. With prolonged strong induction (0.1% L-Ara for 24 h), this strain displayed moderate resistance for ϳ60 to 80% of the population, substantially greater than that of the ⌬phoQ positive control (Fig. 4B) .
Similarly, brief strong induction of the monocistronic cprR WT allele in the ⌬phoQ ⌬cprR strain restored moderate resistance to a subpopulation of ϳ10% (Fig. 4C) , while prolonged strong induction conferred moderate resistance on ϳ60% of the population (Fig. 4D) . In contrast, both brief and prolonged strong induction of the monocistronic cprS WT allele in the ⌬phoQ ⌬cprS strain conferred negligible resistance (Fig. 4E  and F) .
Prolonged weak induction of cprR ؉ S21 mutant allele in the ⌬phoQ ⌬cprRS strain maximally enhances Pm resistance. Whole-genome sequencing of highly Pm r strain 1577 revealed a single point mutation in cprS, C3452226T, resulting in a missense mutation (Arg241Cys) in the CprS histidine kinase domain, close to the predicted His245 active site. This mutant allele, which we have designated cprS21, was also found in the whole-genome sequences of earlier phoQ21 mutants from the same Copenhagen CF patient (Pm s strain 1581 and Pm r strain 1579) and of phoQ21 mutants from a different patient (Pm s strain 1601 and highly Pm r strains 1021 and 1598). To define the role of cprS21 in clinical Pm resistance, it was PCR amplified and inserted into pJN105D.
Prolonged strong induction of the bicistronic cprR ϩ S21 mutant allele in the ⌬phoQ ⌬cprRS strain conferred moderate Pm resistance on ϳ50% of the population, with an MIC of Ͼ100 mg/liter, comparable to the effect of the bicistronic cprRS WT allele (Fig. 5A) . In contrast, prolonged strong induction of the monocistronic cprS21 mutant allele in the ⌬phoQ ⌬cprS strain conferred moderate resistance on only ϳ10% of the population, with an MIC of 100 mg/liter; however, this was substantially greater than the effect of the monocistronic cprS WT allele, which conferred 20% low-level resistance with an MIC of only 20 mg/ liter (Fig. 5B) . Unexpectedly, prolonged weak induction (0.025% L-Ara for 24 h) of the bicistronic cprR ϩ S21 mutant allele conferred high-level Pm resistance (MIC Ͼ 300 mg/liter) on ϳ65% of the population (Fig. 5C ), thus enhancing PhoPQ-mediated Pm resistance to a greater degree than did prolonged strong induction. In contrast, for the bicistronic WT allele, the effect of prolonged weak induction was similar to that of prolonged strong induction, con- ferring ϳ20% moderate resistance and only ϳ5 to 10% high-level resistance.
To determine the effect of cprRS alleles on Pm susceptibility independent of phoQ deletion, bicistronic cprRS WT and cprR ϩ S21 mutant alleles were each expressed in the ⌬cprRS strain with prolonged strong induction. In this strain background, the cprR ϩ S21 mutant allele conferred Pm resistance comparable to that of ⌬phoQ, whereas the cprRS WT allele had no effect (Fig. 5D) . Prolonged strong induction of the monocistronic cprR WT allele in the ⌬cprR strain (strain 4128) conferred low-level resistance on ϳ5 to 10% of the population, while such induction of the monocistronic cprS WT or cprS21 mutant alleles in a ⌬cprS background (strains 4091 and 4093, respectively) had no effect on Pm susceptibility (see Table S3 in the supplemental material).
Prolonged strong induction of the bicistronic cprRS WT or cprR ϩ S21 mutant alleles in ⌬phoQ (strains 4236 and 4238, respectively) failed to augment Pm resistance (see Table S3 ). This indicates that the effect of cprR ϩ S21 is genetically recessive to the chromosomal cprRS WT allele present in this strain background.
DISCUSSION
This work has defined multiple loci necessary for PhoPQ-mediated Pm resistance in P. aeruginosa, including four that encode novel two-component regulatory systems, ColRS and CprRS. Deletion of colR, colS, cprR, or cprS resulted in diminished Pm resistance in a ⌬phoQ background but had no significant effect on susceptibility in a WT background. Prolonged strong induction of bicistronic ColRS in a ⌬phoQ ⌬colRS background restored Pm resistance, whereas brief strong induction of ColRS, or prolonged strong induction of monocistronic ColR or ColS, did not. In contrast, brief strong induction of bicistronic CprRS in a ⌬phoQ ⌬cprRS background restored Pm resistance, as did brief strong induction of monocistronic CprR in a ⌬phoQ ⌬cprR background; prolonged strong induction markedly enhanced the resistance of these strains.
Two-component systems function via phosphorylation of histidine on one protein (the histidine sensor kinase), followed by transfer of phosphate to aspartic acid, usually on a second protein (the response regulator). The histidine sensor kinase is generally bifunctional, with a kinase activity that phosphorylates the response regulator and a phosphatase activity that dephosphorylates it. Overexpressed sensor kinases may exhibit excessive phosphatase activity relative to kinase activity, leading to inactivation of the cognate response regulator (51) ; this may explain the failure of monocistronic ColS and CprS overexpression to complement the corresponding deletion mutants. The failure of monocistronic ColR overexpression to complement ⌬phoQ ⌬colR is more difficult to explain but may be attributable to the timing and/or intensity of its expression under the control of a constitutive non-native promoter. Nonetheless, the deletion and complementation results presented here indicate that the ColRS and CprRS two-component regulatory systems interact with the PhoPQ system to regulate Pm resistance.
The identification of mutant colRS and cprS alleles in a clinical phoQ mutant strain provides additional evidence of interaction among these systems. After transfer to an expression plasmid, prolonged weak induction of the colR21S21 allele in a ⌬phoQ ⌬colRS background or of the cprR ϩ S21 allele in a ⌬phoQ ⌬cprRS background enhanced Pm resistance more than the respective WT alleles did under the same conditions. This suggests that the mutations in the colR21S21 and cprS21 alleles heighten the capacity of each system to activate its regulon. Though episomal expression of these alleles resulted in complementation, the inducing conditions used to accomplish this were chosen through trial and error, without knowledge of the timing and strength of induction of these loci from their native promoters. These empirically determined inducing conditions could have led to a substantial underestimation of resistance enhancement.
In terms of clinical relevance, these results indicate that in Pmexposed clinical strains, second-step mutations in the CprRS and ColRS systems enhance the Pm resistance that first-step mutations in the PhoPQ system confer. Continuous treatment of Copenhagen CF patients with inhaled CST since the early 1980s (11, 52, 53) provided selection pressure for the emergence of highly Pm r CF isolates of P. aeruginosa (23) . The observation that some of these patients were failing to respond to continuous inhaled CST coincided with clinical detection of the phoQ21 mutant and other phoQ mutant strains in the late 1990s. CST inhalation was stopped for such patients, likely facilitating the emergence of Pm s mutants with suppressor mutations in phoP and other loci.
The cprS21 mutant allele was found in six phoQ21 mutants isolated from two Copenhagen CF patients between 1997 and 2002, including two Pm s isolates with presumed secondary suppressor mutations. This indicates that the cprS21 allele arose no later than 1997, presumably in response to the same initial selection pressure that selected for the phoQ21 allele. First-step mutations in phoQ alone result in only low to moderate Pm resistance; data presented here support the hypothesis that second-step mutations, such as that found in the cprS21 allele, contribute to highlevel resistance. Here we have shown that the cprS21 allele remains active in enhancement of PhoPQ-mediated Pm resistance even at low levels of induction, compared to the cprS WT allele. We speculate that this enhanced activity is attributable to the effects of the Arg241Cys H-box mutation in the cytosolic histidine kinase domain, which likely alters phosphatase activity relative to kinase activity of the CprS sensor protein. Such mutations typically activate the cognate response regulator (in this case, CprR), as shown for other two-component systems, including PmrAB (16, (54) (55) (56) .
The subsequent resumption of CST inhalation in Copenhagen CF patients with suppressor mutants provided renewed selection pressure, which presumably promoted reemergence of Pm r strains with mutations in additional loci, such as colRS, that regulate L-Ara4N modification and other resistance mechanisms. The colS21 allele was detected in Pm r phoQ21 mutants isolated in 1999 and 2002, whereas the colR21 allele was detected only in the phoQ21 mutant isolated in 2002. This suggests that the colS21 periplasmic domain mutation represents a discrete step resulting in increased Pm resistance in the phoQ21 cprS21 background, but specific evidence to support this hypothesis is presently lacking. Similarly, we speculate that the activity-enhancing effect of the colR21 allele, which has an Asp32Asn receiver domain mutation, is partial interference with the ColR-ColS interaction. This would diminish the capacity of the ColS histidine sensor kinase to act as a phosphatase, as shown for similar receiver domain mutations in other response regulators (57, 58) . Taken together, these findings support the notion that mutations in the ColRS and CprRS systems represent regulatory mechanisms contributing to high-level clinical Pm resistance.
Other work in P. aeruginosa has shown that the colRS promoter is differentially expressed in the presence of Gram-positive oral flora (Streptococcus and Staphylococcus spp.) from CF patients (59) and that the ColS sensor kinase is necessary for virulence in a Caenorhabditis elegans infection model (47) , implicating the ColRS system in polymicrobial and host-pathogen interactions. ColRS-CprRS homologues were defined initially for P. fluorescens, in which the ColRS system is required for Pm tolerance and efficient root colonization of host plants (45, 60) and subsequently for P. putida, in which this system is required for root colonization (46) , specific transpositional activity (61), phenol tolerance (62, 63) , heavy metal tolerance (64) , and protection against cell lysis in the context of metabolic responses to glucose limitation (63, 65) . Interestingly, oprF (PA1777) and crc (PA5332) mediate this metabolic response in P. putida (65) , and ColRS also regulates the gene product of pagL (PA4661), a lipid A deacylase, in this organism (66) . The present work has implicated all three of these loci in P. aeruginosa Pm resistance. This suggests that the pseudomonads express these genes as part of a coordinated metabolic response protecting against membrane stress.
Single-gene deletion of colS or colR in a ⌬phoQ background decreased or completely eliminated L-Ara4N modification of lipid A, presumably by interfering, either directly or indirectly, with expression of the arnBCADTEF-pmrE operon. Although the mechanism of this interference remains unknown, a variety of noncognate interactions have been observed among two-component regulatory systems of P. aeruginosa and other microbes (67) (68) (69) . Thus, it is plausible that ColR or ColS could, in the absence of its cognate partner, interact aberrantly with PhoP, CprR, or CprS to inhibit aminoarabinosylation of lipid A.
In contrast, tandem deletion of colRS or cprRS in the ⌬phoQ background or single-gene deletion of cprRS in this background abrogated Pm resistance without changing the mass spectral pattern of L-Ara4N modification of lipid A seen for the Pm r ⌬phoQ mutant. These findings provide the first conclusive evidence that L-Ara4N modification alone is not sufficient for Pm resistance in P. aeruginosa and suggest that the ColRS and CprRS systems regulate additional factors necessary for resistance. This finding does not diminish the potential of lipid A aminoarabinosylation as a drug target, as confirmed through transposon (Tn) mutants with arnC or arnT disruption (Table 2 ), but it indicates that other factors could represent additional targets for the development of resistance inhibitors.
Insight into the potential identities of such factors comes from a recent screen of the comprehensive PA14 Tn mutant library, which contains ϳ5800 Tn mutants representing coverage of ϳ4,600 distinct nonessential open reading frames (ORFs), or ϳ90% of the nonessential P. aeruginosa genome. This screen defined only 17 genes as necessary for Mg 2ϩ depletion-induced PMB resistance (70) . The present study analyzed a set of ϳ8,800 Tn mutants estimated to provide coverage of ϳ3,000 distinct nonessential ORFs, or ϳ60% of the nonessential genome (34), implicating 41 genes as necessary for PhoPQ-mediated PMB resistance. Aside from phoPQ itself (PA1179-1180), only two individual genes were implicated in both studies: galU (PA2023) and mpl (PA4020). Both of these studies also implicated adjacent genes (wapR-ssg-hypothetical-mig14-wapH, PA5000-5004) within the LPS core biosynthesis gene cluster (PA4996-5012) (41, 42) . Among the other 12 genes implicated in Mg 2ϩ depletion-induced PMB resistance (70) , pmrA (PA4776) and parR (PA1798) were described previously (16, 19, 26, 27) . The present study has implicated 35 additional genes, of which only arnC (PA3553), arnT (PA3556), and cprS have been previously linked to P. aeruginosa Pm resistance (13, 48, 71) . In addition, our study identified PA1559, encoding a hypothetical protein, as required for PhoPQmediated Pm resistance; the CprRS system has been shown to regulate this locus (48) .
Our transposon screen may have included false positives as a consequence of sporadic secondary suppressor mutations of the phoQ6 allele, which complicated a previous analysis of clinical phoQ mutants (23) . On the other hand, this transposon screen provided only ϳ60% coverage of the nonessential genome and thus may significantly underestimate the total number of genes necessary for PhoPQ-mediated PMB resistance. In addition, both studies fail to account for resistome components that are necessary for PmrAB-or ParRS-mediated PMB resistance but that are not required for PhoPQ-mediated and Mg 2ϩ depletion-induced resistance. These limitations notwithstanding, Ն50 novel genes are presently implicated in the overall PMB resistome of P. aeruginosa, and we strongly suspect that others remain to be discovered.
This work has increased our understanding of P. aeruginosa Pm resistance, revealing unexpected complexity in key molecular mechanisms. At present, five two-component regulatory systems of P. aeruginosa are known to influence resistance to Pm and other cationic antimicrobial peptides: PmrAB (13, 16, 19, 24, 25, 72) , PhoPQ (20, 22, 23, 25, 38, 72) , ParRS (26, 27) , CprRS (48) , and ColRS. Of these, PmrAB, PhoPQ, and ParRS are known targets of first-step mutations resulting in low-to moderate-level Pm resistance. The ColR response regulator represents a novel, nonredundant intermediary that interacts with the PhoPQ system to regulate aminoarabinosylation of lipid A but also other undefined cellular factors necessary for Pm resistance. The CprR response regulator is similarly required for PhoPQ-mediated Pm resistance and has previously been shown to regulate the L-Ara4N biosynthetic locus (48) but is apparently redundant with the PhoP response regulator in this function. Nonetheless, evidence presented here indicates that both the ColRS and CprRS systems regulate required cellular factors besides L-Ara4N. Such cellular factors likely include the hypothetical protein encoded by PA1559 and others of the Ͼ50 novel gene products that transposon mutagenesis has defined as required for PhoPQ-mediated and Mg 2ϩ depletion-induced Pm resistance. Further delineation of these cellular factors is expected to broaden the range of potential targets for development of Pm resistance inhibitors beyond the current focus on L-Ara4N biosynthesis.
